Kestra Advisory Services’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-7,672
| Closed | -$218K | – | 2207 |
|
|
2023
Q1 | $218K | Sell |
7,672
-167
| -2% | -$4.74K | ﹤0.01% | 1782 |
|
|
2022
Q4 | $229K | Buy |
7,839
+88
| +1% | +$2.57K | ﹤0.01% | 1937 |
|
|
2022
Q3 | $205K | Buy |
7,751
+8
| +0.1% | +$212 | ﹤0.01% | 1867 |
|
|
2022
Q2 | $344K | Buy |
7,743
+66
| +0.9% | +$2.93K | ﹤0.01% | 1541 |
|
|
2022
Q1 | $380K | Sell |
7,677
-119
| -2% | -$5.89K | ﹤0.01% | 1447 |
|
|
2021
Q4 | $397K | Buy |
7,796
+2
| +0% | +$102 | ﹤0.01% | 1438 |
|
|
2021
Q3 | $435K | Buy |
7,794
+3
| +0% | +$167 | ﹤0.01% | 1460 |
|
|
2021
Q2 | $333K | Sell |
7,791
-76
| -1% | -$3.25K | ﹤0.01% | 1506 |
|
|
2021
Q1 | $328K | Buy |
7,867
+362
| +5% | +$15.1K | ﹤0.01% | 1414 |
|
|
2020
Q4 | $349K | Buy |
7,505
+7,400
| +7,048% | +$344K | ﹤0.01% | 1394 |
|
|
2020
Q3 | $310K | Buy |
+105
| New | +$310K | 0.01% | 1095 |
|